This Medudy course is a video tutorial for physicians on the topic "10-year outcome with nivolumab & ipilimumab in malignant melanoma". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
Immune checkpoint inhibitors, including PD-1 and CTLA-4 antibodies such as nivolumab and ipilimumab, have changed the treatment of advanced melanoma. In the CheckMate 067 study, the median overall survival after a follow-up period of 6.5 years was 72 months with a combination therapy of nivolumab plus ipilimumab compared to 20 months with ipilimumab alone. The authors are now reporting the final results of the CheckMate 067 study with a follow-up period of at least 10 years.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this course you will know
- the clinical background and relevance of the research question under investigation
- the study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
